PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
30176535-4	2018	The clofarabine-containing compound (2) was shown to be more potent than APCP with IC50 values of 0.18 muM (vs. 3.8 muM) on purified protein and 0.24 muM (vs. 23.6 muM) on CD73 expressed on cells.	Clofarabine	4-15	latexin	Homo sapiens	103-106	
30176535-4	2018	The clofarabine-containing compound (2) was shown to be more potent than APCP with IC50 values of 0.18 muM (vs. 3.8 muM) on purified protein and 0.24 muM (vs. 23.6 muM) on CD73 expressed on cells.	Clofarabine	4-15	latexin	Homo sapiens	116-119	
30176535-4	2018	The clofarabine-containing compound (2) was shown to be more potent than APCP with IC50 values of 0.18 muM (vs. 3.8 muM) on purified protein and 0.24 muM (vs. 23.6 muM) on CD73 expressed on cells.	Clofarabine	4-15	latexin	Homo sapiens	116-119	
30176535-4	2018	The clofarabine-containing compound (2) was shown to be more potent than APCP with IC50 values of 0.18 muM (vs. 3.8 muM) on purified protein and 0.24 muM (vs. 23.6 muM) on CD73 expressed on cells.	Clofarabine	4-15	latexin	Homo sapiens	116-119	
29174506-2	2018	Herein, we identified that clofarabine (4), an FDA-approved drug, displayed potential PDE2 inhibitory activity (IC50 = 3.12 +- 0.67 muM) by structure-based virtual screening and bioassay.	Clofarabine	27-38	latexin	Homo sapiens	132-135